Get help now — free helplines

You can call any of these for free. You do not need a diagnosis, an appointment, or a crisis to call — questions and plain exhaustion are reasons enough.

  • Alzheimer's Association 24/7 Helpline 800-272-3900 24 hours a day, 365 days a year Free, confidential support and information for people with dementia, caregivers, families and the public. Master's-level clinicians. Also Spanish.
  • 988 Suicide & Crisis Lifeline 988 24/7 Call or text 988, or chat at 988lifeline.org. For anyone in emotional distress or a mental-health crisis, including caregivers.
  • Alzheimer's Foundation of America (AFA) Helpline 866-232-8484 9:00 am - 9:00 pm ET, seven days a week Licensed social workers providing support, info and referrals. Also text message and web chat. Text: 646-586-5283

In a medical emergency, call 911. More numbers, and what each line does, on the help page.

This page is alzhub.org's plain-English summary of a published study, not the paper itself. It is generated from the record we hold for this study, sourced and linked below — check the original for the full text and methods.

✓ Peer-reviewed alzhub usefulness score 53 out of 100. TREM2 and immune genetics

Topic: Brain proteins, microglia and lab models

Plain-language summary

TREM2 was suggested to be an important regulator of microglia during neurodegeneration, but previous studies report conflicting results in relation to soluble TREM2 (sTREM2) in cerebrospinal fluid (CSF) when using clinical criteria to classify Alzheimer's disease (AD). The present study explores sTREM2 CSF levels and their associations with other biomarkers and cognitive measures in a prospective AD cohort. Based on the available CSF biomarker information, 497 subjects were classified according to the 2018 National Institute on Aging-Alzheimer's Association research framework guidelines, which group biomarkers into those of amyloid-β deposition, tau pathology, and neurodegeneration.

What this study adds

Evidence grade: Moderate

The record lists 497 participants. In 497 people from a prospective Alzheimer's cohort grouped by spinal-fluid biomarkers, levels of soluble TREM2 (a sign of brain immune activity) were associated with markers of nerve-cell damage and tau, but not with amyloid. Levels rose over time in people with abnormal tau, but were not related to changes in thinking and memory over time.

Taken from this record’s own fields, not from reading the paper. The grade is assigned from the abstract’s wording; what that means.

Cite this study APA, Vancouver, BibTeX · download .bib or .ris

APA 7th

Rauchmann, B. S., Schneider-Axmann, T., Alexopoulos, P., Perneczky, R., & Alzheimer's Disease Neuroimaging Initiative. (2019). CSF soluble TREM2 as a measure of immune response along the Alzheimer's disease continuum. Neurobiology of aging. https://doi.org/10.1016/j.neurobiolaging.2018.10.022

Vancouver

Rauchmann BS, Schneider-Axmann T, Alexopoulos P, Perneczky R, Alzheimer's Disease Neuroimaging Initiative. CSF soluble TREM2 as a measure of immune response along the Alzheimer's disease continuum. Neurobiology of aging. 2019. doi:10.1016/j.neurobiolaging.2018.10.022. PMID: 30458365.

BibTeX

@article{rauchmann2019-30458365,
  author  = {Rauchmann, B. S. and Schneider-Axmann, T. and Alexopoulos, P. and Perneczky, R. and {Alzheimer's Disease Neuroimaging Initiative}},
  title   = {{CSF soluble TREM2 as a measure of immune response along the Alzheimer's disease continuum}},
  journal = {Neurobiology of aging},
  year    = {2019},
  doi     = {10.1016/j.neurobiolaging.2018.10.022},
  pmid    = {30458365},
  url     = {https://doi.org/10.1016/j.neurobiolaging.2018.10.022}
}

Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. Check the citation against the original before you use it.

Key findings

Why it matters

In 497 people from a prospective Alzheimer's cohort grouped by spinal-fluid biomarkers, levels of soluble TREM2 (a sign of brain immune activity) were associated with markers of nerve-cell damage and tau, but not with amyloid. Levels rose over time in people with abnormal tau, but were not related to changes in thinking and memory over time. The authors see it as a possible complementary marker of neuroinflammation; this observational study does not show it can diagnose, treat or prevent Alzheimer's.

Study details

How this study scored 53/100
How this study's score is builtJournal tier 7 of 10; Journal's citation record 3 of 4; Study design 0 of 12; Strength of evidence 3 of 5; Peer-review validation 10 of 10; How recent 2 of 5; Sample size 2 of 4; Effect reported 0 of 3; Studied in people 3 of 3; Randomized / blinded 0 of 2; Times cited 4 of 7; Citations per year 3 of 5; Impact for its field and year 2 of 6; Cited by studies here 3 of 6; Still being cited 2 of 4; Senior author's track record 3 of 4; Institution's track record 2 of 3; Multicenter collaboration 2 of 3; Indexed in PubMed 2 of 2; Free to read 0 of 2. Total 53 of 100.53 of 100 points earned47 not earned

Published in a peer-reviewed journal. Scored zero for study design, effect reported and randomized / blinded because the record does not state it.

ComponentPointsWhy
Journal tier 7 / 10 Tier 3 — peer-reviewed journal (Neurobiology of aging)
Journal's citation record 3 / 4 Neurobiology of Aging: journal h-index 263 (OpenAlex, 2026-10-29)
Study design 0 / 12 No study design recorded — scores zero, not guessed (not stated in the record — scored 0)
Strength of evidence 3 / 5 Rated “moderate” in our summary
Peer-review validation 10 / 10 Peer-reviewed. Published as an article in a named peer-reviewed journal.
How recent 2 / 5 2019 — within 10 year(s) of the newest study here
Sample size 2 / 4 497 participants
Effect reported 0 / 3 No effect size reported — scores zero (not stated in the record — scored 0)
Studied in people 3 / 3 Studied in people (participant count stated)
Randomized / blinded 0 / 2 No randomization or blinding stated — scores zero (not stated in the record — scored 0)
Times cited 4 / 7 Cited 73 times (OpenAlex, 2026-10-10)
Citations per year 3 / 5 8.1 citations a year over 9 year(s) since 2019
Impact for its field and year 2 / 6 Cited 2.9× the average for papers of its field and year (OpenAlex FWCI)
Cited by studies here 3 / 6 Cited by 16 other studies in this library
Still being cited 2 / 4 Cited 24 times in 2024–2026 (2026 still in progress; OpenAlex)
Senior author's track record 3 / 4 Last-listed author Robert Perneczky: h-index 73 (OpenAlex, whole career)
Institution's track record 2 / 3 Imperial College London: institution h-index 1,744 (OpenAlex)
Multicenter collaboration 2 / 3 OpenAlex lists 7 institution(s) in 3 countries
Indexed in PubMed 2 / 2 Indexed in PubMed (PMID 30458365)
Free to read 0 / 2 Behind a paywall — scores zero
Total 53 / 100 —

What each of these 20 components measures, and what this score is not →

Read the original

Full text: free to read — OpenAlex lists this copy as free to read: the link above (checked 6 Feb 1020).

Studies in the library that share something with this one. The line above each title says what.

Studies this one cites

Referenced by this study and also in the alzhub library, so you can read them here. Showing 12 of 37.

Later studies that cite this one

16 studies in the alzhub library list this one in their references. Showing the 8 highest-scoring.

Related studies in TREM2 and immune genetics from nearby years

Also tagged “r47h”

363 studies in the library carry the topic tag “r47h”; these are this study's neighbours in a fixed, alphabetical-by-hash tour of them, not the closest in content. All 363 tagged studies.

Studies sharing this one's topic tags

Similar studies

More on TREM2 and immune genetics

See all studies in TREM2 and immune genetics →